Aldose Reductase

AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.

WJ-39 is a potent orally active inhibitor of aldose reductase (AR), demonstrating significant therapeutic potential. This compound has been shown to mitigate tubular damage in diabetic nephropathy models by activating the PINK1/Parkin signaling pathway, thereby promoting mitophagy and reducing apoptosis. WJ-39 serves as a valuable tool for studying diabetic complications and the underlying mechanisms of kidney injury.

Tolrestat is an aldose reductase inhibitor[1] which was approved for the control of certain diabetic complications.

Epalrestat is an aldose reductase inhibitor.

Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.

Ranirestat is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy.

Sorbinil, is an Aldose reductase inhibitor (ARI).

Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.

Aldose reductase-IN-1 is a inhibitor of aldose reductase with IC50 of 28.9 pM. IC50 value: 28.9 pM Target: aldose reductase Detailed information please refer to WO2014113380 A1 and US20130225592.

Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications

Danshenol A is a potent aldose reductase inhibitor, exhibiting an IC50 of 0.1 μM. This abietane-type diterpenoid demonstrates protective effects on endothelial cells against oxidative stress through direct scavenging of reactive oxygen species (ROS). Additionally, Danshenol A possesses notable anti-inflammatory and antitumor properties, making it a valuable compound for research focused on atherosclerosis and related pathologies.

APPA is an aldose reductase inhibitor that functions by disrupting the polyol pathway, thereby preventing apoptosis associated with diabetic conditions. In preclinical studies, APPA has demonstrated efficacy in alleviating symptoms related to Streptozotocin-induced diabetes in rat models. This compound shows promise for research applications in diabetic nephropathy (DN), offering insights into potential therapeutic strategies.